Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2016-02-19 16:14:21
Reporting Period:
Filing Date:
Accepted Time:
2016-02-19 16:14:21
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1510580 Kite Pharma Inc. KITE Biological Products, (No Disgnostic Substances) (2836) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1609643 R Margo Roberts C/o Kite Pharma, Inc.
2225 Colorado Avenue
Santa Monica CA 90404
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-17 9,632 $0.70 18,730 No 4 M Direct
Common Stock Disposition 2016-02-17 9,532 $45.05 9,198 No 4 S Direct
Common Stock Disposition 2016-02-17 100 $46.01 9,098 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2016-02-17 9,632 $0.00 9,632 $0.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
62,743 2023-10-07 No 4 M Direct
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. 25% of the 150,000 shares subject to the stock option vested and became exercisable on August 19, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.